Dr. Gerhard Hildebrandt, MD
Claim this profileUniversity of Kentucky Markey Cancer Center
Studies Acute Myeloid Leukemia
Studies Leukemia
6 reported clinical trials
16 drugs studied
Area of expertise
1Acute Myeloid Leukemia
t(8;21) negative
inv(16) negative
t(16;16) negative
2Leukemia
t(8;21) negative
inv(16) negative
t(16;16) negative
Affiliated Hospitals
More about Gerhard Hildebrandt, MD
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 1 Active Clinical TrialTreatments Gerhard Hildebrandt, MD has experience with
- Cytarabine
- Daunorubicin
- Hyperbaric Oxygen Therapy
- No Hyperbaric Oxygen Therapy
- CPI-613
- Mitoxantrone
Breakdown of trials Gerhard Hildebrandt, MD has run
Acute Myeloid Leukemia
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Leukemia
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- Blinatumomab + Nivolumab (+/- Ipilimumab) for Acute Lymphoblastic Leukemia
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Myeloid Leukemia
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- Gilteritinib vs Midostaurin for Acute Myeloid Leukemia
Multiple Myeloma
Plasma Cell Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gerhard Hildebrandt, MD specialize in?
Gerhard Hildebrandt, MD focuses on Acute Myeloid Leukemia and Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved t(8;21) negative patients, or patients who are inv(16) negative.
Is Gerhard Hildebrandt, MD currently recruiting for clinical trials?
No, Gerhard Hildebrandt, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Gerhard Hildebrandt, MD has studied deeply?
Yes, Gerhard Hildebrandt, MD has studied treatments such as Cytarabine, Daunorubicin, Hyperbaric Oxygen Therapy.
What is the best way to schedule an appointment with Gerhard Hildebrandt, MD?
Apply for one of the trials that Gerhard Hildebrandt, MD is conducting.
What is the office address of Gerhard Hildebrandt, MD?
The office of Gerhard Hildebrandt, MD is located at: University of Kentucky Markey Cancer Center, Lexington, Kentucky 40536 United States. This is the address for their practice at the University of Kentucky Markey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.